Medical Device News Magazine

Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”) (Nasdaq:IMMX), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced that Dr. Heather Landau has joined the Nexcella Scientific Advisory Board. Dr. Landau brings extensive experience in designing clinical trials in hematology and oncology, novel treatment approaches for AL amyloidosis and multiple myeloma, and thought leadership to Nexcella.

“Patients with relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma deserve more effective treatments that can improve their outcomes,” said Dr. Landau. “Nexcella is leading development of a CAR-T in AL Amyloidosis with encouraging clinical results. I am excited to join the Nexcella Scientific Advisory Board and help advance NXC-201 for U.S. patients with AL Amyloidosis and multiple myeloma.”

“We are delighted to have Dr. Landau join the Nexcella Scientific Advisory Board,” stated Ilya Rachman, Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added: “Dr. Landau’s wealth of experience comes from more than 15 years at MSK, with CAR-Ts and transplantation across indications to bring innovative treatment options to patients is inspirational. We are excited to be collaborating with Dr. Landau.”

Dr. Heather Landau is the Director of Amyloidosis Program and a Bone Marrow Transplant Specialist & Cellular Therapist at Memorial Sloan-Kettering Cancer Center in New York. She has authored more than 100 peer-reviewed publications. Dr. Landau received her medical degree from SUNY Upstate Medical University, completed her Internal Medicine residency at University of Colorado and her Hematology & Oncology fellowship at Memorial Sloan Kettering Cancer Center.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.

ArisGlobal Reports | Newest Version of LifeSphere® Regulatory Platform Launches

Ann-Marie Orange, CIO & Global Head of R&D shares, “With more than 35 years of experience in life sciences technology, ArisGlobal is the only technology company offering strong Safety, Regulatory, and Quality Management solutions powered with next-generation cognitive computing, delivering unmatched interoperability across the R&D IT ecosystem. Over the last 18 months ArisGlobal has made significant investment in the strategic acquisitions of Amplexor Life Sciences and SPORIFY, along with technology R&D – and we’re not stopping.”